<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01280487</url>
  </required_header>
  <id_info>
    <org_study_id>ZSTK474-101</org_study_id>
    <nct_id>NCT01280487</nct_id>
  </id_info>
  <brief_title>A Safety Study of Oral ZSTK474 in Patients With Cancer</brief_title>
  <official_title>A Phase 1b, Multi-Center, Open Label, Uncontrolled, Serial Cohort, Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Daily Oral Doses of ZSTK474 in Subjects With Advanced Solid Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zenyaku Kogyo Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zenyaku Kogyo Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK) and&#xD;
      preliminary efficacy of daily oral doses of ZSTK474, an oral phosphatidylinositol 3-kinase&#xD;
      (PI3K) inhibitor, in subjects with advanced solid malignancies.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose</measure>
    <time_frame>21 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics</measure>
    <time_frame>21 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Neoplasms</condition>
  <arm_group>
    <arm_group_label>Oral ZSTK474</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daily oral dosing for 21 days per cycle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ZSTK474</intervention_name>
    <description>Daily oral dosing for 21 days each cycle</description>
    <arm_group_label>Oral ZSTK474</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or females ≥18 years of age;&#xD;
&#xD;
          2. Histologically-confirmed advanced (metastatic or unresectable) solid tumor - for which&#xD;
             available therapy is not effective;&#xD;
&#xD;
          3. ECOG performance status score of ≤2 and an expected survival of &gt;8 weeks;&#xD;
&#xD;
          4. Recovered from the toxicities of prior chemotherapy, radiotherapy, and other cancer&#xD;
             therapies; all toxicities must be determined to be below Grade 2 (assessed using the&#xD;
             NCI CTCAE v4.0).&#xD;
&#xD;
          5. Adequate blood counts with a hemoglobin (Hgb) of ≥9.0 mg/dL, absolute neutrophil count&#xD;
             (ANC) &gt;1,500/mm3, and platelets ≥100,000/mm3 (all without transfusion support);&#xD;
&#xD;
          6. Subjects who are willing and able to provide written informed consent.&#xD;
&#xD;
        In the expanded cohort at the MTD only: Subjects must be willing to undergo mandatory&#xD;
        biopsies of tumor tissue twice during the first cycle (before and during dosing) and must&#xD;
        have tumor tissue in a location accessible to incisional biopsy of a superficial lesion or&#xD;
        percutaneous core needle biopsy on an outpatient basis without undue risk to the subject.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Women who are pregnant or breastfeeding;&#xD;
&#xD;
          2. Men or women of reproductive potential who are not willing to use acceptable means of&#xD;
             contraception while on study drug and for an additional 90 days after the last dose of&#xD;
             study drug;&#xD;
&#xD;
          3. Body Mass Index (BMI) is ≥30 kg/m2;&#xD;
&#xD;
          4. Have primary central nervous system (CNS) tumors or untreated/uncontrolled CNS&#xD;
             metastases; Note: Subjects with stable/controlled CNS metastases may be enrolled&#xD;
             (i.e., if CNS lesions have been stable in size for at least one month and the subject&#xD;
             is off steroid and anti-convulsants).&#xD;
&#xD;
          5. Have received any investigational interventional agents within the 4 weeks prior to&#xD;
             the start of dosing with ZSTK474;&#xD;
&#xD;
          6. Are receiving concurrent anti-tumor chemotherapy, radiotherapy, or immunotherapy - or&#xD;
             have received any of these non-investigational agents within the previous 4 weeks or&#xD;
             5-half-lives (whichever is longer) prior to the start of dosing with ZSTK474;&#xD;
&#xD;
          7. Are not able or willing to comply with the study procedures, including the study visit&#xD;
             schedule;&#xD;
&#xD;
          8. Have previously been treated with a phosphatidylinositol 3 kinase (PI3K) inhibitor;&#xD;
&#xD;
          9. Have serious or significant intercurrent illnesses or underlying diseases, such as:&#xD;
&#xD;
               1. Diabetes&#xD;
&#xD;
               2. Gastrointestinal disorder&#xD;
&#xD;
               3. Hepatic: AST or ALT &gt;2.5 x ULN (or &gt;5.0 x ULN with liver metastases) or serum&#xD;
                  bilirubin &gt;1.5 x ULN;&#xD;
&#xD;
               4. Renal (acute or chronic renal disease or eGFR &lt;55 mL/min)&#xD;
&#xD;
               5. Cardiovascular:&#xD;
&#xD;
                    -  Uncontrolled hypertension or blood pressure &gt;140/90 mmHg;&#xD;
&#xD;
                    -  Symptomatic congestive heart failure;&#xD;
&#xD;
                    -  Myocardial infarction within the past 6 months;&#xD;
&#xD;
                    -  Unstable angina pectoris;&#xD;
&#xD;
                    -  Cardiac arrhythmia;&#xD;
&#xD;
                    -  Congenital long QT syndrome;&#xD;
&#xD;
                    -  QTc &gt;450 msec for men or &gt;470 msec for women.&#xD;
&#xD;
               6. Other:&#xD;
&#xD;
                    -  Known diagnosis of HIV infection;&#xD;
&#xD;
                    -  Other ongoing or active infections;&#xD;
&#xD;
                    -  Psychiatric illness, substance abuse or social situation that would preclude&#xD;
                       study compliance.&#xD;
&#xD;
                    -  Other serious concurrent illness that would preclude assessment of drug&#xD;
                       effect;&#xD;
&#xD;
                    -  PT/PTT)/APTT/INR &gt;ULN for subjects not on anti-coagulants; INR &gt; 1.5 x ULN&#xD;
                       for subjects on low dose warfarin.&#xD;
&#xD;
         10. Current treatment with the following drugs:&#xD;
&#xD;
               -  any anti-seizure medications;&#xD;
&#xD;
               -  therapeutic anti-coagulant doses of warfarin.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Craig Lockhart, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anthony Olszanski, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fox Chase Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Geoffrey Shapiro, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>St Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2015</verification_date>
  <study_first_submitted>January 18, 2011</study_first_submitted>
  <study_first_submitted_qc>January 19, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 20, 2011</study_first_posted>
  <last_update_submitted>January 15, 2015</last_update_submitted>
  <last_update_submitted_qc>January 15, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 16, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ZSTK474</keyword>
  <keyword>PI3K inhibitor</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

